Article Per Year (5 Year)
p-Index From 2020 - 2025
0.659
P-Index
This Author published in this journals
All Journal The Indonesian Biomedical Journal The Avicenna Medical Journal Kesmas: Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal)
Arifin, Arief Riadi
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Treatment Outcome of Remdesivir Compared to Favipiravir on Moderate Symptoms COVID-19 Arifin, Arief Riadi; Yunus, Faisal; Patrama, Satria; Putra, Muhammad Ryan Adi; Roxanne, Olivia Geraldine
The Avicenna Medical Journal Vol. 4 No. 1 (2023): The Avicenna Medical Journal
Publisher : Faculty of Medicine, UIN Syarif Hidayatullah Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15408/avicenna.v4i1.31132

Abstract

Remdesivir and Favipiravir have been widely used as antiviral agents in treating COVID-19. However, studies providing head on comparison of treatment outcomes between the two antiviruses are rare. The aim of this study is to compare the treatment outcome of Remdesivir and Favipiravir in moderate symptoms COVID-19. Subjects were divided into two groups based on received antivirus during COVID-19 treatment in the hospital, Remdesivir group and Favipiravir group. Post-treatment outcome was measured with three indicators: symptom improvement, negative conversion of RT-PCR, and radiological improvement. Outcomes of both groups were compared with chi square test with Remdesivir serves as a risk factor and Favipiravir as control. Out of a total of 130 subjects, 65 received Remdesivir, and 65 received Favipiravir. Post-treatment RT-PCR and radiologic examination were performed on a median of Day-10 hospitalization. RT-PCR conversion to negative was significantly more likely in Remdesivir group (RR: 1,917, 95% Cl 1,044 – 3,518, p = 0.047, chi square test). There was no significant difference between Remdesivir group and Favipiravir group in symptom improvement on Day-5 (RR 0.941, 95% Cl 0.776 – 1,141), nor Day-7 (RR 1.020, 95% Cl 0.855 – 1.216). There was also no significant difference in radiological improvement (RR 0.855, 95% Cl 0.712 – 1.026). Administering remdesivir to COVID-19 patients significantly increased the occurrence of negative RT-PCR conversion after therapy compared to standard favipiravir therapy.
Epidemiological and Clinical Features of COVID-19 Patients at National Emergency Hospital Wisma Atlet Kemayoran, Jakarta, Indonesia Susanto, Agus Dwi; Rozaliyani, Anna; Prasetyo, Budi; Agustin, Heidy; Baskoro, Hario; Arifin, Arief Riadi; Pratama, Satria; Zaini, Jamal; Hasto, Bambang Dwi; Ratmono, Tugas; Savitri, Ary Indriana; Samoedro, Erlang; Husain, Bahtiar; Nawas, Arifin; Burhan, Erlina
Kesmas Vol. 16, No. 5
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The emergency hospital is intended to prevent transmission of COVID-19 in the community by isolating patients without symptoms, with mild or moderate symptoms. This study evaluated the clinical characteristics and outcomes of COVID-19 patients who were admitted to this facility. This retrospective study re-viewed data of patients treated at the National Emergency Hospital Wisma Atlet Kemayoran in Jakarta, Indonesia, from March 23 to April 30, 2020. Patient characteristics (clinical symptoms, laboratory test results, Chest X-Ray, SARS-CoV-2 immunoserology, and RT-PCR results from nasopharyngeal/ oropharyngeal preparations) were compared between severity groups. There were 413 COVID-19 cases analyzed, of which 190 (46%) were asymptomatic, 93 (22.5%) were mild, and 130 (31.5%) were moderate cases. Most asymptomatic cases were male, with young age, and without comorbidity. Mild cases were dominated by female and young patients, while most moderate cases were male and older patients. The number of patients with comorbidities was higher in mild and mod-erate cases. The patient’s overall outcome was good and did not differ based on the severity of symptoms. Despite the many challenges, patients with moderate symptoms can be safely treated in the emergency hospital.
The Combination of Gardenia jasminoides, Boswellia serrata, Commiphora myrrha, Foeniculum vulgarae, and Daucus carota Essential Oil Blend Improved the Inflammatory and Clinical Status in Respiratory Tract Infection of COVID-19 Patients: A Multicentre, Randomized, Open-label, Controlled Trial Lestari, Keri; Babikian, Haig; Kulsum, Iceu Dimas; Ferdian, Ferdy; Ismail, Efriadi; Sumalim, Yelsen; Setiawan, Setiawan; Santoso, Prayudi; Hartantri, Yovita; Arifin, Arief Riadi; Meiliana, Anna; Sormin, Ida Paulina; Sugiono, Erizal
The Indonesian Biomedical Journal Vol 16, No 3 (2024)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v16i3.3023

Abstract

BACKGROUND: Essential oils (EO) are complex volatile, naturally synthesized compounds from aromatic plants. It considers as healthy, effective, and safe since they were coming from nature. Gardenia jasminoides, Boswellia serrata, Commiphora myrrha, Foeniculum vulgarae, and Daucus carota are known to have antimicrobials, antioxidants, antiinflammation properties against respiratory tract infection. However, despite its natural content, a safety profile needs to be observed. Therefore, in this study, EO blend (EOB) made from the combination of these 5 plants was assessed for its efficacy and safety for respiratory tract infection in human.METHODS: A multicentre, randomized, open-label, phase II controlled trial involving 80 hospitalized adults with COVID-19 was conducted. One group of subjects only received standard of care (SoC), while the other group receive SoC and EOB orally for 10 days.RESULTS: There were significant decrease in interleukin (IL)-6 level (p=0.016) and interferon (IFN)-γ level (p=0.012), as well as better respiratory rate (p=0.024) for the group receiving SoC and EOB compared to the group receiving SoC only. However, there was no significant differences in aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, and the corrected QT interval (QTc) prolongation value in both groups. All subjects with adverse effects were improved and recovered, and there were no serious adverse events found.CONCLUSION: The combination of G. jasminoides, B. serrata, C. myrrha, F. vulgarae, and D. carota EOB could improve the inflammatory and clinical status and safe to be used as adjuvant therapy for treating COVID-19 in adults.KEYWORDS: essential oils, COVID-19, inflammation, safety
Co-Authors Agus Dwi Susanto Agustin, Heidy Anna Meiliana Anna Rozaliyani Arifin Nawas Babikian, Haig Baskoro, Hario Budi Prasetyo Erizal Sugiono, Erizal Erlina Burhan Faisal Yunus Ferdy Ferdian Hasto, Bambang Dwi Husain, Bahtiar Iceu Dimas Kulsum Ida Paulina Sormin Ismail, Efriadi Keri Lestari Patrama, Satria Prayudi Santoso Putra, Muhammad Ryan Adi Roxanne, Olivia Geraldine Samoedro, Erlang Satria Pratama Savitri, Ary Indriana Setiawan Setiawan Sumalim, Yelsen Tugas Ratmono, Tugas Yovita Hartantri Zaini, Jamal